Characterization of the phencyclidine-induced increase in prefrontal cortical dopamine metabolism in the rat

British Journal of Pharmacology

Volumn 124, Issue 2, 1998, Pages 377-385

  Umino, Asami ^a   Takahashi, Kiyohisa ^a,b   Nishikawa, Toru ^a  

^a NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

Author keywords

3,4 Dihydroxyphenylacetic acid; Dopamine; Dopamine utilization; Excitatory amino acid; N methyl D aspartate receptor; Noradrenaline; Phencyclidine; Prefrontal cortex; Striatum; Strychnine insensitive glycine site

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; ALANINE; DOPAMINE; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; MALE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; TISSUE LEVEL;

3,4-DIHYDROXYPHENYLACETIC ACID; ALANINE; ANIMALS; CORPUS STRIATUM; DOPAMINE; DOPAMINE ANTAGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; HALLUCINOGENS; HALOPERIDOL; INJECTIONS, INTRAVENTRICULAR; MALE; N-METHYLASPARTATE; NEURONS, AFFERENT; PHENCYCLIDINE; PREFRONTAL CORTEX; RATS; RATS, WISTAR;

EID: 0031807505     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701830     Document Type: Article

References (43)

1. BAGCHI, S.P. (1981). Effects of phencyclidine on synaptosomal dopamine continuously appearing from phenylalanine: sensitivity to reserpine. Neuropharmacology, 20, 845-851.
2. BJÖRKLUND, A. & LINDVALL, O. (1984). Dopamine-containing systems in the CNS. In Handbook of Chemical Neuroanatomy Vol. 2, Classical Transmitters in the CNS, Part 2, ed. Björklund, A. and Hökfelt, T. pp. 55-122. Amsterdam: Elsevier.
3. BOWERS, M.B. & HOFFMAN, F.J. (1984). Homovanillic acid in rat caudate and prefrontal cortex following phencyclidine and amphetamine. Psychopharmacology, 84, 136-137.
4. BOWYER, J.E., SPUHLER, K.P. & WEINER, N. (1984). Effects of phencyclidine, amphetamine and related compounds on dopamine release from and uptake into striatal synaptosomes. J. Pharmacol Exp. Ther., 229, 671-680.
5. BREIER, A., MALHOTRA, A.K., PINALS, D.A., WEISENFELD, N.I. & PICKAR, D. (1997). Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am. J. Psychiatry, 154, 805-811.
6. BUBSER, M., TZSCHENTKEL, T. & HAUBERL, W. (1995). Behavioural and neurochemical interactions of the AMPA antagonist GYKI 52466 and the non-competitive NMDA antagonist dizocilpine in rats. J. Neural Transm. Gen. Sect., 101, 115-126.
7. CARBONI, E., TANDA, G.L., FRAU, R. & DI CHIARA, G. (1990). Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J. Neurochem., 55, 1067-1070.
8. COLLINGRIDGE, G.L. & LESTER, R.A.J. (1989). Excitatory amino acid receptors in the vertebrate central nervous system. Pharmacol. Rev., 40, 145-210.
9. CONTRERAS, P.C. (1990). D-Serine antagonized phencyclidine- and MK-801-induced stereotyped behavior and ataxia. Neuropharmacology, 29, 291-293.
10. CREESE, I. (1983). Stimulants: Neurochemical, Behavioral and Clinical Perspectives. New York: Raven Press.
11. DEUTCH, A.Y., TAM, S.Y., FREEMAN, A.S., BOWERS, M.B.J. & ROTH, R.H. (1987). Mesolimbic and mesocortical dopamine activation induced by phencyclidine: Contrasting pattern to striatal response. Eur. J. Pharmacol., 134, 257-264.
12. DEUTSCH, S.I., MASTROPAOLO, J., SCHWARTZ, B.L., ROSSE, R.B. & MORIHISA, J.M. (1989). A 'glutamatergic hypothesis' of schizophrenia. Clin. Neuropharmacol., 12, 1-13.
13. DOLAN, R.J., FLETCHER, P., FRITH, C.D., FRISTON, K.J., FRACKOWIAK, R.S.J. & GRASBY, P.M. (1995). Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia. Nature. 378, 180-182.
14. 3H-catecholamines by rat striatal and hypothalamic synaptosomes. Life Sci., 18, 1105-1110.
15. HATA, N., NISHIKAWA, T., UMINO, A. & TAKAHASHI. K. (1990). Evidence for involvement of N-methyl-D-aspartate receptor in tonic inhibitory control of dopaminergic transmission in rat medial prefrontal cortex. Neurosci. Lett., 120, 101-104.
16. HONDO, H., YONEZAWA, Y., NAKAHARA, T., NAKAMURA, K., HIRANO, M., UCHIMURA, H. & TASHIRO, N. (1994). Effect of phencyclidine on dopamine release in the rat prefrontal cortex: An in vivo microdialysis study. Brain Res., 633, 337-342.
17. JEDEMA. HP & MOGHADDAM, B (1996). Characterization of excitatory amino acid modulation of dopamine release in the prefrontal cortex of conscious rats. J. Neurochem., 66, 1448-1453.
18. KASHIWA. A., NISHIKAWA, T. NISHIJIMA, K., UMINO, A. & TAKAHASHI, K (1995). Dizocilpine (MK-801) elicits a tetrodotoxin-sensitive increase in extracellular release of dopamine in rat medial prefrontal cortex. Neurochem. Int., 26, 2269-2279.
19. KEMP, J.A., FOSTER, A.C. & WONG, E.H.F. (1987). Non-competitive antagonists of excitatory amino acid receptors. Trends Neurosci., 294, 1294-1298.
20. KÖNIG, J.F.R. & KLIPPEL, R.A. (1963). The Rat Brain: A Stereotaxic Atlas of the Forebrain and Lower Parts of the Brain Stem. Baltimore: The Williams and Willkins Co.
21. LE MOAL, M. & SIMON, H. (1991). Mesocorticolimbic dopaminergic network: functional and regulatory roles. Physiol. Rev., 71, 155-210.
22. LOWRY, O.H., ROTHENBROUGH, N.J., FARR, A.L. & RANDALL, R.J. (1951). Protein measurement with the folin phenol reagent. J. Biol. Chem., 193, 265-275.
23. MAURICE, T., VIGNON, J., KAMENKA, J.M. & CHICHEPORTICHE, R. (1991). Differential interaction of phencyclidine-like drugs with the dopamine uptake complex in vivo. J. Neurochem., 56, 553-559.
24. NISHIJIMA, K., KASHIWA, A., HASHIMOTO, A., IWAMA, H., UMINO, A. & NISHIKAWA, T. (1996). Differential effects of phencyclidine and methamphetamine on dopamine metabolism in rat prefrontal cortex and striatum as revealed by in vivo dialysis. Synapse, 22, 304-312.
25. NISHIJIMA, K., KASHIWA, A. & NISHIKAWA, T. (1994). Preferential stimulation of extracellular release of dopamine in rat prefrontal cortex to striatum following competitive inhibition of the N-methyl-D-aspartate receptor. J. Neurochem., 63, 375-378.
26. NISHIKAWA, T., FAGE, D. & SCATTON, B. (1986). Evidence for, and nature of, the tonic inhibitory influence of habenuloinerpeduncular pathways upon cerebral dopaminergic transmission in the rat. Brain Res., 373, 324-336.
27. NISHIKAWA, T. & SCATTON, B. (1983). Evidence for a GABAergic inhibitory influence on serotonergic neurons originating from the dorsal raphe. Brain Res., 279, 325-329.
28. NISHIKAWA, T., UMINO, A., TANII, Y., HASHIMOTO, A., HATA, N., TAKASHIMA, M., TAKAHASHI, K. & TORU, M. (1991). Dysfunction of excitatory amino acidergic systems and schizophrenic disorders. In Biological Basis of Schizophrenic Disorders. ed. Nakazawa, T. pp. 65-76, Tokyo and Basel: Japan Scientific Societies Press and Karger.
29. OKUBO, Y., SUHARA, T., SUZUKI, K., KOBAYASHI, K., INOUE, O., TERASAKI, O., MATSUSHIMA, E., IYO, M., TATENO, Y. & TORU, M. (1997). Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature, 385, 634-636.
30. PAXINOS, G. & WATSON, C. (1986). The Rat Brain in Stereotaxic Coordinates. 2nd edn. Sydney: Academic Press.
31. POZZI, L., INVERNIZZI, R., CERVO, L., VALLEBUONA, F. & SAMANIN, R. (1994). Evidence that extracellular concentrations of dopamine are regulated by noradrenergic neurons in the prefrontal cortex of rats. J. Neurochem., 63, 195-200.
32. RAO, T.S., KIM, H.S., LEHMANN, J., MARTIN, L.L. & WOOD, P.L. (1990). Selective activation of dopaminergic pathways in the mesocortex by compounds that act at the phencyclidine (PCP) binding site: Tentative evidence for PCP recognition sites not coupled to N-methyl-D-aspartate (NMDA) receptors. Neuropharmacology, 29, 225-230.
33. SCATTON, B. (1977). Differential regional development of tolerance to increase in dopamine turnover upon repeated neuroleptic administration. Eur. J. Pharmacol., 46, 863-869.
34. SCATTON, B., GLOWINSKI, J. & JULOU, L. (1975). Neuroleptics: effects on dopamine synthesis in nigro-neostriatal, mesolimbic and mesocortical dopaminergic systems. In Antipsychotic Drugs: Pharmacodynamics and Pharmacokinetics. ed. Sedvall, G., Uvenas, B. & Zotterman, I. pp. 243-255. Oxford: Pergamon.
35. SESACK, S.R. & BUNNEY, B.S. (1987). Central dopaminergic systems: Neurophysiology and electrophysiological pharmacology. In Handbook of Schizophrenia Vol. 2: Neurochemistry and Neuropharmacology of Schizophrenia. ed. Henn, F.A. & Delisi, L.E. pp. 149-178. Amsterdam. Elsevier.
36. SHARMAN, D.F. (1981). The turnover of catecholamines. In Central Neurotransmitter Turnover. ed. Pycock, C.J. & Taberner, P.V. pp. 20-58. Baltimore: University Park Press.
37. 3H]-serotonin uptake in synaptosomal preparations from rat brain. Biochem. Pharmacol., 26, 1435-1439.
38. TANII, Y., NISHIKAWA, T., HASHIMOTO, A. & TAKAHASHI, K. (1994). Stereoselective antagonism by enantiomers of alanine and serine of phencyclidine-induced hyperactivity, stereotypy and ataxia in the rat. J. Pharmacol. Exp. Ther., 263, 1040-1048.
39. TANII, Y., NISHIKAWA, T., HASHIMOTO, A. & TAKAHASHI, K. (1991). Stereoselective inhibition by D- and L-alanine of phencyclidine-induced locomotor stimulation in the rat. Brain. Res., 563, 281-284.
40. TANII, Y., NISHIKAWA, T., UMINO, A. & TAKAHASHI, K. (1990). Phencyclidine increases extracellular dopamine metabolites in rat medial prefrontal cortex as measured by in vivo dialysis. Neurosci. Lett., 112, 318-323.
41. VERSTEEG, D.H., VAN DER GUGTEN, J., DE JONG, W. & PALKOVITS, M. (1976). Regional concentrations of noradrenaline and dopamine in rat brain. Brain Res., 113, 563-574.
42. VICKROY, T.W. & JOHNSON, K.M. (1982). Similar dopamine releasing action of phencyclidine and non-amphetamine stimulants in the rat striatum. J. Pharmacol. Exp. Ther., 223, 669-674.
43. ZETTERSTRÖM, T., SHARP, T., COLLIN, A.K. & UNGERSTEDT, U. (1988). In vivo measurement of extracellular dopamine and DOPAC in rat striatum after various dopamine-releasing drugs; implications for the origin of extracellular DOPAC. Eur. J. Pharmacol., 148, 327-334.